Efficacy and tolerability of azelastine nasal spray in the treatment of allergic rhinitis: Large scale experience in community practice

Current Medical Research and Opinion

Volumn 13, Issue 10, 1997, Pages 617-626

  Wober, W ^a   Diez Crespo, C ^b   Bahre M ^c  

^a MIM   (Germany)

^b ASTA Medica SA   (Spain)

^c ASTA MEDICA AG   (Germany)

Author keywords

Allergic rhinitis; Azelastine; Post marketing surveillance; Topical treatment

Indexed keywords

AZELASTINE;

ADOLESCENT; ADULT; AEROSOL; AGED; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PUBLIC HEALTH; SCHOOL CHILD; SYMPTOM;

EID: 0030805181     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007999709113335     Document Type: Article

References (18)

1. Achterrath-Tuckermann, U., Simmet, T., Luck, W., Szelenyi, I., and Peskar, B. A., (1988). Inhibition of cysteinyl-leukotriene production by azelastine and its biological significance. Agents Action., 24, 217-223.
2. Charpin, D., Godard, P., Garay, R., Baehre, M., Herman, D., and Michel, F.B., (1995). A multicentre clinical study of the efficacy and tolerability of azelastine nasal spray in the treatment of seasonal allergic rhinitis: a comparison with oral cetirizine. Eur. Arch. Otorhinolaryngol., 252, 455-458.
3. Ciprandi, G., Pronzanto, C., Passalacqua, G., Ricca, V., Verese, P., Bertolini, C., Bagnasco, M., and Canonica, G. W., (1996). Topical azelastine reduces ICAM-1 expression on nasal epithelial cells: an anti-allergic activity. J. Allerg. Clin. Immunol., 12, 1088-1096.
4. Conde Hernandez, J., Palma Aguilar, J. L., and Delgado Romero, J., (1995). Comparison of azelastine nasal spray and oral ebastine in treating seasonal allergic rhinitis. Curr. Med. Res. Opin., 13, 299-304.
5. Davies, R. J., Lund, V. J., and Harten-Ash, V. J., (1993). The effect of intranasal azelastine and beclomethasone on the symptoms and signs of nasal allergy in patients with perennial allergic rhinitis. Rhinol., 31, 159-164.
6. Dorow, P., Aurich, R., and Petzold, U., (1993). Efficacy and tolerability of azelastine nasal spray in patients with nasal allergy compared to placebo and budesonide. Arzneim.-Forsch./Drug Res., 43, 909-912.
7. Gastpar, H., Aurich, R., Petzold, U., Dorow, P., Enzmann, H., Gerling, R., Köchy, K. P., Philipp, A., Renz, W., and Wendenburg, G., (1993). Intranasal treatment of perennial allergic rhinitis: azelastine nasal spray versus budesonide aerosol. Arzneim.-Forsch./Drug Res., 43, 475-479.
8. Gastpar, H., (1990). Comparison of efficacy and tolerability of azelastine nasal spray and budenoside nasal aerosol in patients with perennial allergic rhinitis. Study No. 2730, ASTA Pharma AG.
9. Gastpar, H., (1989). Comparison of the efficacy and tolerability of an azelastine nasal spray with those of terfenadine on 6-week treatment of patients with allergic rhinitis (perennial). Study No. 2613, ASTA Pharma AG.
10. Gering, R., (1990). Comparison of efficacy and tolerability of azelastine nasal spray, azelastine tablets, and astemizole in the treatment of seasonal allergic rhinitis. Study No. 2758, ASTA Pharma AG.
11. Herman, D., Garay, R., and Le Gal, M., (1997). A randomised double-blind placebo controlled study of azelastine nasal spray in children with perennial rhinitis. Int. J. Ped. Otorhinolaryngol., 39, 1-8.
12. Kurzeja, A. H., (1989). Comparison of the efficacy and tolerability of an azelastine HCl nasal spray with those of terfenadine on 6-week treatment of patients with allergic rhinitis. Study No. 2610, ASTA Pharma AG.
13. Laessig, W., Wober, W., Hoflich, C., Bähre, M., and Roloff, A., (1996). Topical therapy for allergic rhinitis in childhood: Allergodil® nasal spray - non-sedating in children. Curr. Med. Res. Opin., 13, 391-395.
14. Masuo, M., Shimada, T., and Kitazawa, T., (1992). Mechanism of inhibitory effects of azelastine on smooth muscle contraction. J. Pharmacol. Exp. Ther., 260, 1300-1308.
15. McTavish, D., and Sorkin, E. M., (1989). Azelastine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs, 38, 778-800.
16. Morganroth, J., Perhach, J. L., Lyness, W., and Rosenberg, A., (1995). Lack of effect of azelastine alone and co-administered with ketoconazole on electrocardiographic parameters. J. Allerg. Clin. Immunol., 95, 282.
17. Mösges, R., Spaeth, J., Conrad, F., and Giani, G., (1995) Azelastine - Nasenspray in der allergologischen Praxis. HNO aktuell, 3, 173-176.
18. Nolte, D., (1989). Comparison of the efficacy and tolerability of azelastine HCl nasal spray with those of terfenadine on 6-weeks treatment of patients with allergic rhinitis (seasonal). Study No. 2606, ASTA Pharma AG.